LQDA
Liquidia Corporation
NASDAQ · Healthcare · Biotechnology · US
$68.66
+0.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 450.9M | 158.3M | 14.0M | 17.5M | 15.9M |
| Cost of Revenue | 33.9M | 13.2M | 5.9M | 2.9M | 2.9M |
| Gross Profit | 417.0M | 145.1M | 8.1M | 14.6M | 13.1M |
| Operating Expenses | |||||
| R&D Expense | 55.7M | 39.3M | 47.8M | 43.2M | 19.4M |
| SG&A Expense | 192.7M | 157.2M | 81.6M | 44.7M | 32.4M |
| General & Admin Expense | 145.7M | 157.2M | 81.6M | 44.7M | 32.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 248.4M | 196.5M | 129.4M | 88.0M | 51.8M |
| Cost and Expenses | 282.3M | 209.7M | 135.3M | 90.9M | 54.7M |
| Operating Income (EBIT) | 168.6M | (51.4M) | (121.3M) | (73.4M) | (38.8M) |
| Non-Operating | |||||
| Interest Income | 7.6M | 6.6M | 7.7M | 3.5M | 1.1M |
| Interest Expense | 26.6M | 24.2M | 12.5M | 6.3M | 2.3M |
| Net Interest Income | (19.1M) | (17.5M) | (4.8M) | (2.8M) | (1.2M) |
| Other Non-Op Income/Expense | (19.1M) | (17.5M) | (9.1M) | (5.1M) | (2.2M) |
| Non-Operating Income (excl Interest) | (7.6M) | (6.6M) | (3.4M) | (1.2M) | (93.0K) |
| EBT (Pre-Tax Income) | 149.5M | (68.9M) | (130.4M) | (78.5M) | (41.0M) |
| Income Tax Expense | 10.9M | — | — | — | — |
| Bottom Line | |||||
| Net Income | 138.6M | (68.9M) | (130.4M) | (78.5M) | (41.0M) |
| Earnings from Cont. Ops | 138.6M | (68.9M) | (130.4M) | (78.5M) | (41.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 138.6M | (68.9M) | (130.4M) | (78.5M) | (41.0M) |
| Per Share | |||||
| Basic EPS | $1.57 | ($0.80) | ($1.66) | ($1.21) | ($0.67) |
| Diluted EPS | $1.37 | ($0.80) | ($1.66) | ($1.21) | ($0.67) |
| Revenue Per Share | $5.07 | $1.84 | $0.18 | $0.27 | $0.26 |
| Shares | |||||
| Basic Shares Outstanding | 88.9M | 86.1M | 78.7M | 65.0M | 61.0M |
| Diluted Shares Outstanding | 101.4M | 86.1M | 78.7M | 65.0M | 61.0M |
| Profitability Metrics | |||||
| EBITDA | 177.8M | (43.2M) | (115.7M) | (70.1M) | (35.0M) |
| D&A | 1.7M | 1.5M | 2.2M | 2.2M | 3.6M |
| EBIT | 176.1M | (44.8M) | (117.9M) | (72.2M) | (38.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026